Inhibitory effects of BiRyuChe-bang on mast cell-mediated allergic reactions and inflammatory cytokines production.
BiRyuChe-bang (BRC) is a Korean prescription medicine, which has been used to treat allergic rhinitis at Kyung Hee Medical Center. In this work, we investigated the effects of BRC on mast cell-mediated allergic reactions and inflammatory cytokines production, and identified the active component of BRC. Histamine release was measured from rat peritoneal mast cells (RPMCs). Ear swelling and passive cutaneous anaphylaxis (PCA) were examined in mouse models. Phorbol 12-myristate 13-acetate (PMA) plus A23187-induced inflammatory cytokines production was measured using enzyme-linked immunosorbent assay. Reverse transcriptase-polymerase chain reaction was used for the expressions of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-8. Activation of nuclear factor (NF)-κB was analyzed by Western blotting. BRC significantly inhibited the compound 48/80-induced ear swelling response, histamine release from RPMCs, PCA activated by anti-dinitrophenyl IgE, and PMA plus A23187-induced inflammatory cytokines production (p < 0.05). In addition, BRC dose-dependently inhibited the mRNA expressions of TNF-α, IL-6, and IL-8 as well as the activation of NF-κB in a human mast cell line, HMC-1 cells. BRC inhibited the levels of TNF-α and IL-6 in mice induced with PCA. Several components of BRC, such as 1,8-Cineole, Linalool, Linalyl acetate, α-Pinene, and α-Terpineol, significantly inhibited the release of histamine from RPMCs (p < 0.05). Among these components, Linalyl acetate was the most effective for inhibiting histamine release. These results indicate that BRC has a potential regulatory effect on allergic and inflammatory reactions mediated by mast cells.
Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
Phil-Dong
PD
Moon
Il Sang
IS
Choi
Ji-Hyun
JH
Go
Byong-Joo
BJ
Lee
Sang Woo
SW
Kang
Sunhee
S
Yoon
Seung-Jun
SJ
Han
Sun-Young
SY
Nam
Hyun-A
HA
Oh
Na-Ra
NR
Han
Young-Sick
YS
Kim
Ju-Sung
JS
Kim
Myong-Jo
MJ
Kim
Hyun-Ja
HJ
Jeong
Hyung-Min
HM
Kim
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D008297:Male; D008407:Mast Cells / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D008813:Mice, Inbred ICR; D039821:Monoterpenes / Q000302:isolation & purification / Q000494:pharmacology; D016328:NF-kappa B; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects*; D010537:Peritoneum / Q000166:cytology; D051381:Rats; D017208:Rats, Wistar; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives / Q000494:pharmacology
D016207:Cytokines; D004365:Drugs, Chinese Herbal; D018836:Inflammation Mediators; D039821:Monoterpenes; D016328:NF-kappa B; D000001:Calcimycin; C020922:4-O-methyl-12-O-tetradecanoylphorbol 13-acetate; C074463:linalyl acetate; D013755:Tetradecanoylphorbol Acetate